A theme covering the performance trajectory of the bioindustry support business, centered on research-use reagents, from a period of revenue and profit growth that drove overall performance to a shift into an operating loss due to declining sales of reagents, equipment and genetic medicine, a higher cost ratio, acquisition-related expenses and amortization of goodwill.